HIV相关NAFLD治疗反应的MRI评估:硬脂酰辅酶A去饱和酶-1抑制剂随机试验(ARRIVE试验)
ARRIVE试验为双盲随机安慰剂对照研究,纳入50例HIV相关NAFLD患者,随机接受阿拉莫醇600mg每日一次或安慰剂治疗12周。主要终点MRI-PDFF肝脂肪变化在两组间无差异,MRE和VCTE肝硬度及全身脂肪肌肉组成也无差异。结论认为12周阿拉莫醇未减少肝脂肪或改变体脂肌肉组成。
要点
- 阿拉莫醇组与安慰剂组MRI-PDFF平均变化无差异(-1.3% vs -1.4%)。
- 两组MRI-PDFF相对下降无差异(6.8% vs 1.1%,P=0.68)。
- MRE和VCTE肝硬度及全身脂肪肌肉组成分析均无差异。
核心结论
- 在HIV相关NAFLD患者中,12周阿拉莫醇治疗未减少肝脂肪,也未改变基于MRI评估的体脂和肌肉组成。
研究设计与样本
- ARRIVE试验为双盲、随机、研究者发起的安慰剂对照试验,测试阿拉莫醇12周治疗HIV相关NAFLD的疗效。
- 50例MRI-PDFF≥5%的HIV相关NAFLD患者随机接受阿拉莫醇600mg每日一次(n=25)或安慰剂(n=25)治疗12周。
- 主要终点为共定位感兴趣区MRI-PDFF测定的肝脂肪变化。
主要发现
- 阿拉莫醇组平均MRI-PDFF变化为-1.3%(基线15.6% vs 治疗结束14.4%,P=0.24),安慰剂组为-1.4%(基线13.3% vs 治疗结束11.9%,P=0.26),两组间无差异。
- 阿拉莫醇组与安慰剂组MRI-PDFF相对下降无差异(6.8% vs 1.1%,P=0.68)。
- MRE衍生和VCTE衍生肝硬度以及MRI或DXA全身脂肪和肌肉组成分析均无差异。
- 与基线相比,阿拉莫醇组治疗结束转氨酶降低,安慰剂组未降低。
- 无显著不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)-associated NAFLD is unknown. The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV-associated NAFLD. Fifty patients with HIV-associated NAFLD, defined by magnetic resonance imaging (MRI)-proton density fat fraction (PDFF) ≥5%, were randomized to receive either aramchol 600 mg daily (n = 25) or placebo (n = 25) for 12 weeks. The primary endpoint was a change in hepatic fat as measured by MRI-PDFF in colocalized regions of interest. Secondary endpoints included changes in liver stiffness using magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE), and exploratory endpoints included changes in total-body fat and muscle depots on dual-energy X-ray absorptiometry (DXA), whole-body MRI, and cardiac MRI. The mean (± standard deviation) of age and body mass index were 48.2 ± 10.3 years and 30.7 ± 4.6 kg/m2 , respectively. There was no difference in the reduction in mean MRI-PDFF between the aramchol group at -1.3% (baseline MRI-PDFF 15.6% versus end-of-treatment MRI-PDFF 14.4%, P = 0.24) and the placebo group at -1.4% (baseline MRI-PDFF 13.3% versus end-of-treatment MRI-PDFF 11.9%, P = 0.26). There was no difference in the relative decline in mean MRI-PDFF between the aramchol and placebo groups (6.8% versus 1.1%, P = 0.68). There were no differences in MRE-derived and VCTE-derived liver stiffness and whole-body (fat and muscle) composition analysis by MRI or DXA. Compared to baseline, end-of-treatment aminotransferases were lower in the aramchol group but not in the placebo arm. There were no significant adverse events. Conclusion: Aramchol, over a 12-week period, did not reduce hepatic fat or change body fat and muscle composition by using MRI-based assessment in patients with HIV-associated NAFLD (clinicaltrials.gov ID:NCT02684591).
引用
- Ajmera VH, Cachay E, Ramers C, et al. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial). Hepatology. 2019. PMID: 31013363. doi:10.1002/hep.30674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。